Eric Joseph
Stock Analyst at JP Morgan
(1.25)
# 2,583
Out of 4,412 analysts
86
Total ratings
36.36%
Success rate
-15.45%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Reiterates: Overweight | $25 | $13.47 | +85.60% | 3 | Apr 18, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $55 → $50 | $21.98 | +127.48% | 1 | Feb 27, 2024 | |
| VIR Vir Biotechnology | Maintains: Neutral | $9 → $10 | $8.23 | +21.51% | 3 | Feb 23, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $34 → $47 | $33.37 | +40.85% | 2 | Feb 23, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Underweight | $12 → $11 | $12.37 | -11.08% | 3 | Feb 8, 2024 | |
| CCCC C4 Therapeutics | Upgrades: Neutral | $6 | $6.17 | -2.76% | 4 | Jan 29, 2024 | |
| BEAM Beam Therapeutics | Upgrades: Overweight | $38 → $40 | $21.38 | +87.09% | 2 | Jan 29, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Neutral | $11 → $10 | $8.12 | +23.15% | 2 | Nov 13, 2023 | |
| RVMD Revolution Medicines | Maintains: Overweight | $47 → $39 | $35.96 | +8.45% | 3 | Nov 7, 2023 | |
| PRME Prime Medicine | Maintains: Overweight | $27 → $26 | $4.43 | +487.57% | 2 | Nov 7, 2023 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $31 → $11 | $5.33 | +106.38% | 2 | Oct 19, 2023 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $62 → $41 | $19.74 | +107.70% | 2 | Oct 11, 2023 | |
| LYEL Lyell Immunopharma | Downgrades: Neutral | $15 → $5 | $2.17 | +130.41% | 1 | Aug 28, 2023 | |
| IPSC Century Therapeutics | Downgrades: Neutral | $28 → $5 | $2.88 | +73.61% | 2 | Aug 28, 2023 | |
| PLRX Pliant Therapeutics | Maintains: Overweight | $47 → $48 | $11.81 | +306.44% | 3 | Aug 10, 2023 | |
| AVIR Atea Pharmaceuticals | Downgrades: Underweight | n/a | $3.71 | - | 5 | Aug 10, 2023 | |
| TERN Terns Pharmaceuticals | Maintains: Neutral | $10 → $11 | $4.91 | +124.03% | 6 | Aug 9, 2023 | |
| IGMS IGM Biosciences | Maintains: Neutral | $26 → $19 | $9.40 | +102.13% | 3 | May 16, 2023 | |
| HLVX HilleVax | Maintains: Overweight | $23 → $22 | $12.79 | +72.01% | 2 | May 16, 2023 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $57 → $64 | $28.57 | +124.01% | 3 | May 8, 2023 | |
| BLUE bluebird bio | Initiates: Overweight | $7 | $0.92 | +658.56% | 1 | Apr 28, 2023 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $42 → $29 | $6.37 | +355.26% | 3 | Apr 19, 2023 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $37 → $36 | $12.36 | +191.26% | 4 | Feb 13, 2023 | |
| SRZN Surrozen | Downgrades: Underweight | n/a | $8.98 | - | 2 | Nov 29, 2022 | |
| NVAX Novavax | Downgrades: Underweight | $132 → $27 | $4.09 | +560.15% | 5 | Sep 22, 2022 | |
| KPTI Karyopharm Therapeutics | Upgrades: Neutral | $8 | $1.06 | +654.72% | 2 | Feb 9, 2022 | |
| ALGS Aligos Therapeutics | Downgrades: Neutral | $30 → $12 | $0.78 | +1,434.53% | 1 | Jan 7, 2022 | |
| OMER Omeros | Downgrades: Underweight | n/a | $3.15 | - | 2 | Oct 8, 2021 | |
| VERV Verve Therapeutics | Initiates: Neutral | n/a | $6.16 | - | 1 | Jul 12, 2021 | |
| ACHL Achilles Therapeutics | Initiates: Underweight | n/a | $0.76 | - | 1 | Apr 26, 2021 | |
| AUTL Autolus Therapeutics | Downgrades: Neutral | n/a | $4.00 | - | 2 | Jan 29, 2021 | |
| AKBA Akebia Therapeutics | Downgrades: Underweight | n/a | $1.34 | - | 1 | Jan 29, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Overweight | n/a | $5.89 | - | 1 | Feb 24, 2020 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Neutral | n/a | $7.82 | - | 2 | Jan 24, 2019 | |
| SGMO Sangamo Therapeutics | Maintains: Neutral | n/a | $0.52 | - | 2 | Nov 14, 2018 | |
| OPK OPKO Health | Downgrades: Underweight | n/a | $1.26 | - | 2 | Mar 2, 2018 |
TG Therapeutics
Apr 18, 2024
Reiterates: Overweight
Price Target: $25
Current: $13.47
Upside: +85.60%
Rocket Pharmaceuticals
Feb 27, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $21.98
Upside: +127.48%
Vir Biotechnology
Feb 23, 2024
Maintains: Neutral
Price Target: $9 → $10
Current: $8.23
Upside: +21.51%
Kymera Therapeutics
Feb 23, 2024
Maintains: Overweight
Price Target: $34 → $47
Current: $33.37
Upside: +40.85%
Enanta Pharmaceuticals
Feb 8, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $12.37
Upside: -11.08%
C4 Therapeutics
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $6.17
Upside: -2.76%
Beam Therapeutics
Jan 29, 2024
Upgrades: Overweight
Price Target: $38 → $40
Current: $21.38
Upside: +87.09%
Recursion Pharmaceuticals
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $8.12
Upside: +23.15%
Revolution Medicines
Nov 7, 2023
Maintains: Overweight
Price Target: $47 → $39
Current: $35.96
Upside: +8.45%
Prime Medicine
Nov 7, 2023
Maintains: Overweight
Price Target: $27 → $26
Current: $4.43
Upside: +487.57%
Monte Rosa Therapeutics
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $5.33
Upside: +106.38%
Akero Therapeutics
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $19.74
Upside: +107.70%
Lyell Immunopharma
Aug 28, 2023
Downgrades: Neutral
Price Target: $15 → $5
Current: $2.17
Upside: +130.41%
Century Therapeutics
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.88
Upside: +73.61%
Pliant Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $47 → $48
Current: $11.81
Upside: +306.44%
Atea Pharmaceuticals
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.71
Upside: -
Terns Pharmaceuticals
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $4.91
Upside: +124.03%
IGM Biosciences
May 16, 2023
Maintains: Neutral
Price Target: $26 → $19
Current: $9.40
Upside: +102.13%
HilleVax
May 16, 2023
Maintains: Overweight
Price Target: $23 → $22
Current: $12.79
Upside: +72.01%
PTC Therapeutics
May 8, 2023
Maintains: Overweight
Price Target: $57 → $64
Current: $28.57
Upside: +124.01%
bluebird bio
Apr 28, 2023
Initiates: Overweight
Price Target: $7
Current: $0.92
Upside: +658.56%
Relay Therapeutics
Apr 19, 2023
Maintains: Overweight
Price Target: $42 → $29
Current: $6.37
Upside: +355.26%
Nurix Therapeutics
Feb 13, 2023
Maintains: Overweight
Price Target: $37 → $36
Current: $12.36
Upside: +191.26%
Surrozen
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $8.98
Upside: -
Novavax
Sep 22, 2022
Downgrades: Underweight
Price Target: $132 → $27
Current: $4.09
Upside: +560.15%
Karyopharm Therapeutics
Feb 9, 2022
Upgrades: Neutral
Price Target: $8
Current: $1.06
Upside: +654.72%
Aligos Therapeutics
Jan 7, 2022
Downgrades: Neutral
Price Target: $30 → $12
Current: $0.78
Upside: +1,434.53%
Omeros
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.15
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Neutral
Price Target: n/a
Current: $6.16
Upside: -
Achilles Therapeutics
Apr 26, 2021
Initiates: Underweight
Price Target: n/a
Current: $0.76
Upside: -
Autolus Therapeutics
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.00
Upside: -
Akebia Therapeutics
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.34
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Overweight
Price Target: n/a
Current: $5.89
Upside: -
Ironwood Pharmaceuticals
Jan 24, 2019
Upgrades: Neutral
Price Target: n/a
Current: $7.82
Upside: -
Sangamo Therapeutics
Nov 14, 2018
Maintains: Neutral
Price Target: n/a
Current: $0.52
Upside: -
OPKO Health
Mar 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $1.26
Upside: -